5 Microcap Stocks With 65% or More Upside Potential
While they do carry higher-than-average risk, these microcaps also offer major upside potential for investors seeking startup-sized returns.
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...